| 12.13 0.47 (4.03%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 17.92 | 1-year : | 20.77 |
| Resists | First : | 15.34 | Second : | 17.79 |
| Pivot price | 13.72 |
|||
| Supports | First : | 11.39 | Second : | 9.48 |
| MAs | MA(5) : | 12.73 |
MA(20) : | 14.29 |
| MA(100) : | 11.97  |
MA(250) : | 7.85 |
|
| MACD | MACD : | -0.5 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 7.6 |
D(3) : | 16.8 |
| RSI | RSI(14): 41.5 |
|||
| 52-week | High : | 17.79 | Low : | 2.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OLMA ] has closed above bottom band by 19.2%. Bollinger Bands are 48.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.55 - 12.63 | 12.63 - 12.7 |
| Low: | 11.41 - 11.49 | 11.49 - 11.57 |
| Close: | 12 - 12.12 | 12.12 - 12.25 |
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Wed, 06 Dec 2023
Will Olema Pharmaceuticals Inc (OLMA) Stay at the Top of the Healthcare Sector? - InvestorsObserver
Thu, 30 Nov 2023
Is Olema Pharmaceuticals Inc (OLMA) a Bad Choice in Biotechnology Thursday? - InvestorsObserver
Tue, 28 Nov 2023
Olema Pharmaceuticals Stock: Advancing On Multiple Fronts (NASDAQ:OLMA) - Seeking Alpha
Mon, 27 Nov 2023
Olema Pharmaceuticals (OLMA) Skyrockets 471% YTD: Here's Why - Yahoo Finance
Sat, 25 Nov 2023
Insiders Of Olema Pharmaceuticals Sold Some Of Their Shares - Simply Wall St
Thu, 09 Nov 2023
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 26 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 82.8 (%) |
| Shares Short | 2,760 (K) |
| Shares Short P.Month | 2,190 (K) |
| EPS | -2.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.03 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24.3 % |
| Return on Equity (ttm) | -39 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -85 (M) |
| Levered Free Cash Flow | -45 (M) |
| PE Ratio | -5.26 |
| PEG Ratio | 0 |
| Price to Book value | 2.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|